During the past decade, Beijing Tsinghua Changgung Hospital conducted 63 clinical trials. In the 10-year time frame, 63 clinical trials started and 3 clinical trials were completed, i.e. on average, 4.8% percent of trials that started reached the finish line to date. In the past 5 years, 54 clinical trials started and 3 clinical trials were completed. i.e. 5.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Beijing Tsinghua Changgung Hospital" #1 sponsor was "Beijing Tsinghua Chang Gung Hospital" with 24 trials, followed by "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 6 trials sponsored, "Eli Lilly and Company" with 5 trials sponsored, "Bayer" with 3 trials sponsored and "Boehringer Ingelheim" with 3 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 26 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Beijing Tsinghua Changgung Hospital" #1 collaborator was "Beijing Tsinghua Chang Gung Hospital" with 2 trials as a collaborator, "Beijing Tsinghua Changgeng Hospital" with 2 trials as a collaborator, "Peking University First Hospital" with 2 trials as a collaborator, "Ruijin Hospital" with 2 trials as a collaborator and "Ankang Central Hospital" with 1 trials as a collaborator. Other collaborators include 34 different institutions and companies that were collaborators in the rest 44 trials.

According to Clinical.Site data, the most researched conditions in "Beijing Tsinghua Changgung Hospital" are "Hepatocellular Carcinoma" (6 trials), "Atrial Fibrillation" (3 trials), "Obesity" (3 trials), "Overweight" (3 trials) and "Carotid Artery Plaque" (2 trials). Many other conditions were trialed in "Beijing Tsinghua Changgung Hospital" in a lesser frequency.

Most popular intervention types in "Beijing Tsinghua Changgung Hospital" are "Drug" (35 trials), "Device" (8 trials), "Procedure" (6 trials), "Other" (5 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Tirzepatide" (4 trials), "Finerenone (BAY94-8862)" (2 trials), "Sintilimab" (2 trials) and "AF standard management and OSA general care" (1 trials). Other intervention names were less common.

The vast majority of trials in "Beijing Tsinghua Changgung Hospital" are 62 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Beijing Tsinghua Changgung Hospital". 4 are not yet recruiting, 25 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Beijing Tsinghua Changgung Hospital, 2 suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Beijing Tsinghua Changgung Hospital, 3 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 10 trials that are defined as “Not Applicable".